Literature DB >> 6538424

Single-dose pharmacokinetics of the MAO-inhibitor moclobemide in man.

J Raaflaub, P Haefelfinger, K H Trautmann.   

Abstract

The single-dose kinetics of the MAO-inhibitor p-chloro-N-(2-morpholinoethyl)-benzamide (moclobemide, Ro 11-1163) following oral and i.v. administration to six healthy subjects is described. The dosage was 50 mg throughout (1 tablet moclobemide orally, 2.0 ml ampoule moclobemide i.v.). The unchanged drug in plasma was measured by means of an HPLC-assay. The i.v. plasma level curves were analyzed assuming a two-compartment model. The drug was rapidly distributed into the tissue compartment and was then eliminated from the body with a mean half-life t 1/2 beta of about 1 h (range 0.79-1.34 h). The volume of distribution Vss was of medium size (range 0.81-1.25 l/kg). The oral bioavailability was reduced in consequence of the effect of the first passage through the liver and amounted to 44% on average (range 27-70%). As to the drug absorption from the intestinal tract the extent and rate of this process were shown to be large (more than 95% absorbed on average, tmax-values within 1 h).

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6538424

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  7 in total

1.  Gastric decontamination performed 5 min after the ingestion of temazepam, verapamil and moclobemide: charcoal is superior to lavage.

Authors:  O Lapatto-Reiniluoto; K T Kivistö; P J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  2000-03       Impact factor: 4.335

2.  Plasma moclobemide and metabolites: lack of correlation with clinical response and biogenic amines.

Authors:  J Fritze; G Laux; E Sofic; P Koronakis; M P Schoerlin; P Riederer; H Beckmann
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

3.  Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Danish University Antidepressant Group.

Authors:  L F Gram; K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1993-06       Impact factor: 4.335

Review 4.  Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide.

Authors:  M Mayersohn; T W Guentert
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

5.  Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites.

Authors:  F A Wiesel; J Raaflaub; R Kettler
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 6.  Pharmacokinetic optimisation of therapy with newer antidepressants.

Authors:  P J Goodnick
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447

7.  Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor.

Authors:  N H Holford; T W Guentert; J Dingemanse; L Banken
Journal:  Br J Clin Pharmacol       Date:  1994-05       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.